Patients taking Eli Lilly's new drug Mounjaro achieved significantly greater weight loss than those on Novo Nordisk'sResearchers analyzed the electronic health records of more than 18,000 US patients between May 2022 and September 2023 to compare outcomes among those receiving the two injected medicines, and published the results inThe average age of the patients was 52, more than 70 percent were female, and the average baseline weight was 110 kilograms .
Both drugs, also known by their generic names tirzepatide and semaglutide , belong to a class known as GLP-1 analogs that mimic a naturally occurring hormone andOverall, nearly 82 percent of the Mounjaro group saw five percent or greater weight loss compared to 67 percent of the Ozempic group. The results were 62 percent versus 37 percent for 10 percent or greater weight loss, and 42 percent versus 18 percent for 15 percent or greater weight loss, all in favor of Mounjaro.
At 12 months, the average patient on Mounjaro lost seven percent more weight than the average for Ozempic.that led to its approval, but this was the first time the two drugs were tested against one another. No significant differences were noted in the rates of adverse events between the two groups, though discontinuation of the drug was common among both sets of patients.
Law Law Latest News, Law Law Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ForbesTech - 🏆 318. / 59 Read more »
Source: ScienceAlert - 🏆 63. / 68 Read more »
Source: Medscape - 🏆 386. / 55 Read more »
Source: Health - 🏆 396. / 53 Read more »
Source: SciTechDaily1 - 🏆 84. / 68 Read more »
Source: ABC - 🏆 471. / 51 Read more »